Pronostic factors of chronic lymphoid leukemia;Facteurs pronostiques de la leucemie lymphoide chronique

Hematologie

Volumn 6, Issue 3, 2000, Pages 219-225

  Levy, V ^a   Delmer, A ^a   Ajchenbaum Cymbalista, F ^a  

^a HÔTEL DIEU   (France)

Author keywords

Chronic lymphocytic leukemia; Prognosis

Indexed keywords

CD23 ANTIGEN; CYCLIN D1; FAS ANTIGEN; GLYCOPROTEIN; PROTEIN BCL 2; PROTEIN P27;

CHRONIC LEUKEMIA; CHRONIC LYMPHATIC LEUKEMIA; DISEASE CLASSIFICATION; DISEASE COURSE; HUMAN; LEUKEMIA; LIFE EXPECTANCY; PROGNOSIS; REVIEW;

EID: 0033874906     PISSN: 12647527     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (60)

1. Chronic lymphocytic leukemia
2. The National cancer data base report on age, gender, treatment, and outcomes of patients with chronic lymphocytic leukemia
3. Clinical staging of chronic lymphocytic leukemia
4. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis
5. Randomized cinical trial comparing two anthracyclin-containing regimen (CHOP and CAP) and fludarabine (FDR) in advanced chronic lymphocytic leukemia
6. Natural history of stage A chronic lymphocytic leukaemia untreated patients
7. Effects of chlorambucil and therapeutic decision in initial forms of chronic lymphocytic leukemia (stage A): Results of a randomized clinical trial on 612 patients
8. Prognosis of chronic lymphocytic leukemia: A multivariate regression analysis of 325 untreated patients
9. National cancer institute-sponsored working group guidelines for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatment
10. Prognostic factors in chronic lymphocytic leukaemia: The importance of age, sex and response to treatment in survival. A report from the MRC CLL 1 trial. MRC Working party on leukaemia in adults
11. Prognosis in chronic lymphocytic leukemia: A retrospective multicentric study from the GIMEMA group
12. Lymphocyte doubling time in chronic lymphocytic leukaemia: Analysis of its prognostic significance
13. Natural history of chronic lymphocytic leukemia: An the progression and progression and prognosis of early clinical stages
14. Total tumour mass score (TTM): A new parameter in chronic lymphacyte leukaemia
15. Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy
16. Further characterization of morphologically defined typical and atypical CLL: A clinical, immunophenotypic, cytogenetic and prognostic study on 390 cases
17. The concept of typical and atypical chronic lymphocylic leukaemia
18. Towards a clinically relevant cytogenetic classification of chronic lymphocytic leukemia and related disorders
19. Cytogenetic and molecular cytogenetic analysis of B cell chronic lymphocytic leukemia: Specific chromosome aberrations identify prognostic subgroups of patients and point to loci of candidate genes
20. Improvement of the chronic lymphocytic leukemia scoring system with the monoclonal antibody SN8 (CD79b)
21. The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL
22. Atypical lymphocyte morphology: An adverse prognostic factor for disease progression in stage A CLL independent of trisomy 12
23. Chronic lymphocytic leukemia: Staging and prognostic factors
24. Serum beta(2)-microglobulin and serum thymidine kinase are independent predictors of progression-free survival in chronic lymphocytic leukemia and immunocytoma
25. Prognostic importance of serum soluble CD23 level in chronic lymphocytic leukemia
26. Prognostic impact of the serum levels of soluble CD23 in B-cell chronic lymphocytic leukemia
27. Trisomy 12 in B-cell chronic lymphocytic leukemia: Correlation with advanced disease, atypical morphology, high levels of sCD25, and with refractoriness to treatment
28. Application of an in vitro assay for serum thymidine kinase: Results on viral disease and malignancies in humans
29. Serum deoxythymidine kinase correlates with peripheral lymphocyte thymidine uptake in chronic lymphocytic leukemia
30. Elevated serum thymidine kinase levels identify a subgroup at high risk of disease progression in early, nonsmoldering chronic lymphocytic leukemia
31. Prognostic significance of serum thymidine kinase (sTK) levels and p27KIP1 expression in chronic lymphocytic leukemia
32. Molecular cytogenetic analysis of B-cell chronic lymphocytic leukemia
33. Cytogenetics in chronic lymphocytic leukemia
34. The prognostic significance of 13q 14 deletions in chronic lymphocytic leukemia
35. Trisomy 12 defines a group of CLL with atypical morphology: Correlation between cytogenetic, clinical and laboratory features in 544 patients
36. Cytogenetic and molecular abnormalities in chronic lymphocytic leukaemia
37. Genetic abnormalities in chronic lymphocytic leukemia and their clinical and prognostic implications
38. Atypical chronic lymphocytic leukaemia with t(11;14)(q13;q32): Karyotype evolution and prolymphocytic transfarmation
39. Somatic ATM mutations indicate a pathogenic role of ATM in B-cell chronic lymphocytic leukemia
40. 11q deletions identify a new subset of B-cell chronic lymphocytic leukemia characterized by extensive nodal involvement and inferior prognosis
41. The search for genetic clues in chronic lymphocytic leukemia
42. Cyclin D1 overexpression allows identification of an aggressive subset of leukemic lymphoproliferative disorder
43. Unmutated lg V(H) genes are associated with a more aggressive form of chronic lymphacytic leukemia
44. Mutational status of lg V(H) genes provides clinically valuable information in B-cell chronic lymphocytic leukemia
45. Analysis of somatic mutation in five B cell subsets of human tonsil
46. lg V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia
47. The nature of the B lymphocyte in B-chronic lymphocytic leukemia
48. Antisense-mediated suppression of bcl-2 highlights its pivotal role in failed apoptosis in B-cell chronic lymphocytic leukaemia
49. Molecular pathways in low grade B-cell lymphoma
50. + B cells the expression of BCL-2 gene family is shifted toward protection from apoptosis
51. Ligation of CD40 potentiates Fas-mediated activation of the cysteine protease CPP32, cleavage of its death substrate PARP, and apoptosis in Ramos-Burkitt lymphoma B cells
52. Bcl-2, Bax and p53 expression in B-CLL in relation to in vitro survival and clinical progression
53. Regulation of clinical chemoresistance by bcl-2 and bax oncoproteins in B-cell chronic lymphocytic leukaemia
54. Expression and function of the FAS antigen in B chronic lymphocytic leukemia and hairy cell leukemia
55. Role of the CD40 and CD95 (APO-1/Fas) antigens in the apoptosis of human B-cell malignancies
56. Regulation of B-CLL apoptosis through membrane receptors and Bcl-2 family proteins
57. Prognostic significance of the cell cycle inhibitor p27Kip1 in chronic B-cell lymphocytic leukemia
58. Sequential analysis of p27KIP1 expression in B-CLL allows to predict disease progression
59. Methodological aspects of a clinical trial in chronic lymphocytic leukemia: Necessity to develop new biostatistical methods